2018
Levodopa improves response inhibition and enhances striatal activation in early-stage Parkinson's disease
Manza P, Schwartz G, Masson M, Kann S, Volkow ND, Li CR, Leung HC. Levodopa improves response inhibition and enhances striatal activation in early-stage Parkinson's disease. Neurobiology Of Aging 2018, 66: 12-22. PMID: 29501966, PMCID: PMC6436810, DOI: 10.1016/j.neurobiolaging.2018.02.003.Peer-Reviewed Original ResearchConceptsEarly-stage Parkinson's diseaseParkinson's diseaseDopaminergic medicationAdvanced Parkinson's diseaseStriatal activationResponse inhibitionRole of dopaminergicAge-matched controlsFunctional magnetic resonance imagingMagnetic resonance imagingExecutive functionLevodopa monotherapyMultiple medicationsMotor symptomsSignificant group differencesPD groupStop-signal taskAdvanced stageLevodopaResonance imagingMedicationsFunctional connectivityCritical executive functionMotor inhibitionPatients
2017
Response inhibition in Parkinson’s disease: a meta-analysis of dopaminergic medication and disease duration effects
Manza P, Amandola M, Tatineni V, Li CR, Leung HC. Response inhibition in Parkinson’s disease: a meta-analysis of dopaminergic medication and disease duration effects. Npj Parkinson's Disease 2017, 3: 23. PMID: 28702504, PMCID: PMC5501877, DOI: 10.1038/s41531-017-0024-2.Peer-Reviewed Original ResearchDopamine replacement therapyEarly-stage Parkinson's diseaseDisease durationParkinson's diseaseDopaminergic medicationDopaminergic drugsDisease patientsResponse inhibitionCognitive functionDisease duration effectHallmark motor symptomsParkinson's disease durationShorter disease durationAdvanced Parkinson's diseaseParkinson's disease patientsRole of dopamineResponse inhibition deficitsMotor symptomsBasal gangliaHealthy controlsMedication statusMedicationsPatientsCognitive deficitsNeurodegenerative disorders